Repurposing Arthritis Drug for Graft-vs-Host-Disease
July 10, 2018 | Terry Sharrer
MAIN intentionally ignores drug development, which is a huge field in itself. But cell technology is in our scope, and this story from Washington University in St. Louis about a rheumatoid arthritis drug preventing rejection of stem cell transplants (so far in animal studies) is relevant to us. According to this piece, about half of stem cell transplant recipients present graft-vs-host symptoms, and an inflammation inhibitor used to suppress arthritis shut down the harmful immune response while simultaneously increasing T-cell function against leukemia. MORE
Image Credit: Washington University in St. Louis News